Lv3
340 积分 2022-04-01 加入
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics
2天前
已完结
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
2个月前
已完结
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
2个月前
已完结
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
2个月前
已完结
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
7个月前
已完结
Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer
7个月前
已完结
Effectiveness of S-1–Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma
7个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
11个月前
已完结
Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
1年前
已完结
Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2–IA3 EGFR-Mutated NSCLC: ADAURA2
1年前
已完结
皖公网安备34019202002308
